EN | TR
E-ISSN: 2149-6447
Procedure Guideline for Scintigraphic Imaging in Cardiac Transthyretin Amyloidosis
PDF
Cite
Share
Request
Guideline
VOLUME: 6 ISSUE: 2
P: 190-198
July 2020

Procedure Guideline for Scintigraphic Imaging in Cardiac Transthyretin Amyloidosis

Nucl Med Semin 2020;6(2):190-198
DOI: 10.4274/nts.galenos.2020.0013
Elif Özdemir 1
Fevziye Canbaz Tosun 2
Gülay Durmuş Altun 3
Hakan Demir 4
Semra Özdemir 5
Feyza Şen 6
1. Ankara Yıldırım Beyazıt Üniversitesi Tıp Fakültesi, Nükleer Tıp Anabilim Dalı, Ankara, Türkiye
2. Ondokuz Mayıs Üniversitesi Tıp Fakültesi, Nükleer Tıp Anabilim Dalı, Samsun, Türkiye
3. Trakya Üniversitesi Tıp Fakültesi, Nükleer Tıp Anabilim Dalı, Edirne, Türkiye
4. Kocaeli Üniversitesi Tıp Fakültesi, Nükleer Tıp Anabilim Dalı, Kocaeli, Türkiye
5. Onsekiz Mart Üniversitesi Tıp Fakültesi, Nükleer Tıp Anabilim Dalı, Çanakkale, Türkiye
6. Uludağ Üniversitesi Tıp Fakültesi, Nükleer Tıp Anabilim Dalı, Bursa, Türkiye
No information available.
No information available
Publish Date: 25.08.2020
PDF
Cite
Share
Request

ABSTRACT

Amyloidosis is a multisystem disease that results from extracellular deposition of amyloid fibriles in tissue and cardiac involvement may be seen. Cardiac amyloidosis is a rare and mostly underdiagnosed cause of heart failure. Several types of amyloid can infiltrate the myocardium. Diagnosis is usually made with endomyocardial biopsy. Scintigraphic imaging with Technetium (Tc-99m) labelled biphosponates may facilitate early detection of cardiac involvement and distinguish various forms of cardiac amyloidosis. The aim of this guideline is to assist nuclear medicine physicians in recommending, imaging, reporting and interpreting the results of scintigraphy with Tc-99m labelled bone radiopharmaceuticals for the evaluation of transthyretin cardiac amyloidosis.

References

1
Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet 2016;387:2641-2654.
2
Çavuşoğlu Y, Özpelit E, Çelik A, et al. Cardiac amyloidosis: Recent advances in the diagnosis and therapy. Turk Kardiyol Dern Ars 2019;47(Suppl 2):1-34.
3
Dorbala S, Ando Y, Bokhari S, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-Evidence base and standardized methods of imaging. J Nucl Cardiol 2019;26:2065-2123.
4
Treglia G, Glaudemans AWJM, Bertagna F, et al. Diagnostic accuracy of bone scintigraphy in the assessment of cardiac transthyretin-related amyloidosis: a bivariate meta-analysis. Eur J Nucl Med Mol Imaging 2018;45:1945-1955.
5
Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation 2016;133:2404-2412.
6
Dorbala S, Bokhari S, Miller E, Bullock-Palmer R, Soman P, Thompson R. ASNC Practice Points, 99mTechnetium-Pyrophosphate Imaging for Transthyretin Cardiac Amyloidosis.
7
Dorbala S, Bokhari S, Glaudemans Andor WJM, et al. ASNC and EANM Cardiac Amyloidosis Practice Points 99mTechnetium-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) and 99mTechnetium hydroxymethylene diphosphonate (HMDP) Imaging for Transthyretin Cardiac Amyloidosis.
8
Perugini E, Guidalotti PL, Salvi F, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 2005;46:1076-1084.
9
Yang JC, Fox J, Chen C, Yu AF. Cardiac ATTR amyloid nuclear imaging-not all bone scintigraphy radionuclide tracers are created equal. J Nucl Cardiol 2018 Oct;25:1879-1884.
10
Bokhari S, Castaño A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. (99m) Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging 2013;6:195-201.